» Articles » PMID: 33409553

Chronic Stress Promotes Acute Myeloid Leukemia Progression Through HMGB1/NLRP3/IL-1β Signaling Pathway

Overview
Specialty General Medicine
Date 2021 Jan 7
PMID 33409553
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor prognosis and overall survival. Clinical investigations show that chronic stress is commonly present in the course of AML and associated with adverse outcome. However, the underlying molecular mechanisms are elusive. In the present study, a chronic restraint stress mouse model was established to evaluate the effect of stress on AML. We found that mice under chronic stress exhibited significantly increased liver and spleen infiltration of leukemic cells and poorer overall survival. This was accompanied by elevated cellular NLR family pyrin domain containing 3 (NLRP3) and interleukin-1β (IL-1β) in the liver or bone marrow, and secreted IL-1β in the plasma, indicating the activation of inflammasomes under chronic restraint stress. High mobility group box 1 (HMGB1) expression was markedly increased in newly diagnosed AML patients, but reduced in complete remission AML patients. The expression level of HMGB1 was positively correlated with NLRP3 mRNA in AML patients. Knockdown of HMGB1 significantly decreased NLRP3 and IL-1β expression in AML cell lines, and secreted IL-1β in supernatant of AML cell culture, while HMGB1 stimulation caused contrary effects. These results implied that HMGB1 could be involved in the regulation of inflammasome activation in AML development. Mice model showed that chronic restraint stress-facilitated proliferation and infiltration of AML cells were largely abrogated by knocking down HMGB1. Knockdown of HMGB1 also ameliorated overall survival and remarkably neutralized NLRP3 and IL-1β expression under chronic restraint stress. These findings provide evidences that chronic stress promotes AML progression via HMGB1/NLRP3/IL-1β dependent mechanism, suggesting that HMGB1 is a potential therapeutic target for AML. KEY MESSAGES: • Chronic restraint stress promoted acute myeloid leukemia (AML) progression and mediated NLRP3 inflammasome activation in xenograft mice. • HMGB1 mediated NLRP3 inflammasome activation in AML cells. • Knockdown of HMGB1 inhibited AML progression under chronic stress in vivo.

Citing Articles

Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML.

Sieberer H, Luciano M, Amend D, Blochl C, Eglseer A, Steinkellner A Cell Commun Signal. 2025; 23(1):53.

PMID: 39875995 PMC: 11773904. DOI: 10.1186/s12964-025-02046-w.


Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?.

Jalali A, Mitchell K, Pompoco C, Poludasu S, Tran S, Ramana K Int J Mol Sci. 2025; 25(24.

PMID: 39769450 PMC: 11728390. DOI: 10.3390/ijms252413689.


Single-cell transcriptome profiling of mA regulator-mediated methylation modification patterns in elderly acute myeloid leukemia patients.

Wang Z, Du X, Zhang P, Zhao M, Zhang T, Liu J Mol Biomed. 2024; 5(1):66.

PMID: 39641872 PMC: 11624184. DOI: 10.1186/s43556-024-00234-7.


Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.

Brem S Brain Behav Immun Health. 2024; 42:100859.

PMID: 39512605 PMC: 11541944. DOI: 10.1016/j.bbih.2024.100859.


Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis.

Luciano M, Sieberer H, Krenn P, Dang H, Vetter J, Neuper T Cell Commun Signal. 2024; 22(1):424.

PMID: 39223663 PMC: 11367831. DOI: 10.1186/s12964-024-01777-6.


References
1.
Chida Y, Hamer M, Wardle J, Steptoe A . Do stress-related psychosocial factors contribute to cancer incidence and survival?. Nat Clin Pract Oncol. 2008; 5(8):466-75. DOI: 10.1038/ncponc1134. View

2.
Reiche E, Nunes S, Morimoto H . Stress, depression, the immune system, and cancer. Lancet Oncol. 2004; 5(10):617-25. DOI: 10.1016/S1470-2045(04)01597-9. View

3.
Spiegel D, Giese-Davis J . Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003; 54(3):269-82. DOI: 10.1016/s0006-3223(03)00566-3. View

4.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

5.
Sims G, Rowe D, Rietdijk S, Herbst R, Coyle A . HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010; 28:367-88. DOI: 10.1146/annurev.immunol.021908.132603. View